Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

pies. RA is estimated to affect more than two million people in the U.S. and is a leading cause of morbidity, disability and reduced work ability. The exact cause of RA is unknown, but is believed to reflect the body's immune system attack on the synovium, the tissue that lines the joints.

CCX354 is one of four drug candidates that have been discovered and developed by ChemoCentryx that are also part of an alliance between the Company and GlaxoSmithKline (GSK).  Successful completion of CARAT-2 triggered GSK's option rights under the collaboration agreement, and ChemoCentryx expects GSK's decision whether to exercise its option to obtain a license to further develop and commercialize CCX354 by the end of 2011.

About ChemoCentryxChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's most advanced drug candidate, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. ChemoCentryx's lead independent drug candidate, CCX140-B, a CCR2 inhibitor, has been shown to be safe and well tolerated w
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
(Date:8/29/2014)... 29, 2014 Pixcelldata, the innovative ... has announced a major new deal with Dutch based ... pathology expert, Dr. Marius Nap . ... European Congress of Pathology which is taking placing between ... London where Pixcelldata will demonstrate ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... Highly regarded audiologist , Dr. Mary Ann Larkin has written ... reports are titled:, , Revealing the Truth About ... The Top 5 Things You Should Know Before Buying ... Children , Dr. Mary Anne Larkin choose to write ... and misinformation about each them. The reports are available for ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- Astronauts may be ... to disrupt human immune systems, a new study suggests. ... long missions to asteroids, the moon and Mars undertaken ... while in space can be dangerous, NASA researchers say. ... in the blood of International Space Station crew members ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to announce ... their practice. Dr. Chuang garners extensive experience in the ... arthroscopic and reconstructive treatments of the knees, hips, and ... general and sports-related orthopedic needs. , Dr. ... As an Orange County native, he graduated with two ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 Pursuing ... is set to unveil a stunning new design ... to company figures, the highly notable surrogacy platform has ... January. With over 13,000 visitors a month, the FindSurrogateMother.com ... mothers working toward one common goal — the precious ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3
... 27 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... FBR Capital,Markets 12th Annual Spring Investor Conference on ... York City. Christopher Christensen, CEO, together with Alan,Norman, ...
... E-Connect Statewide to Discuss Successes and Challenges, ... million children,in California experience an emotional or behavioral ... receive adequate treatment. A lack of knowledge,stigma, limited ... and treatment, putting children at risk for school ...
... Healthcare Consulting Team, ANNAPOLIS, Md., May 27 ... leader in the case management field, has joined ... Ms. Craig, architect of the best-in-class caseload,workflow application, ... Mr. Garry Carneal, SHS President and CEO. "Kathy ...
... disease, study says , , TUESDAY, May 27 (HealthDay News) -- ... even in nonsmokers, researchers report. , The findings -- that ... developing lung cancer, regardless of whether he or she ever ... disease, said study author Dr. Ping Yang, of the Mayo ...
... Kevin Hutchinson to Inaugural Board of Managers, ... chief,executive officer, Kevin Hutchinson, has been named an ... LLC, a wholly owned subsidiary of the,American Academy ... consulting services to primary care physicians and health,systems ...
... Calif., May 27 Animal Dermatology Clinic (ADC),Tustin announces ... the new,Member-At-Large on the Executive Board of the American ... ACVD oversees the,operation of and is the decision making ... term. The Member-at-Large position entails Dr.,Muse being a liaison ...
Cached Medicine News:Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 3Health News:Techno-Savvy Public Awareness Campaign Enables Families to Send a Powerful Message About Children's Mental Health 2Health News:Acuity Workflow Solutions(TM) Enhances Medical Case Management Process: 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3Health News:Prematics CEO Joins Initiative to Advance More Coordinated, Connected Health Care 2Health News:Prematics CEO Joins Initiative to Advance More Coordinated, Connected Health Care 3Health News:Animal Dermatology Clinic Tustin Announces Dr. Russell Muse's Appointment as the Member-At-Large for the Executive Board of the American College of Veterinary Dermatology 2
The Trans-Blot transfer cell, used with the included PowerPac 200 power supply, performs efficient, high-intensity electrophoretic transfers. The Trans-Blot cell offers many advantages....
... for a Range of ... Native Enzyme, High Intensity, ... Faster, Higher-Efficiency Transfers via ... Field-Intensity Transfers with Movable ...
... Includes: Criterion cell for running ... with plate electrodes. A blotter fit ... Criterion precast gel system, the Criterion ... the flexibility of the Trans-Blot system ...
A blotter fit for use with the incredible new Criterion precast gel system, the Criterion blotter combines excellent blotting efficiency with the flexibility of the Trans-Blot system and the ease-of-...
Medicine Products: